Propofol infusion syndrome (PRIS) is a rare, often fatal condition of unknown etiology that is associated with hyperlipidemic serum, metabolic acidosis, rhabdomyolysis, hepatomegaly, cardiac arrhythmias, and acute renal failure. To identify risk factors and biomarkers for PRIS, all PRIS cases who may have received her 3 or more consecutive propofol infusions over the course of a year in her ICU patient aged 18 years or older in a level 1 trauma hospital. A retrospective analysis was performed. Additional inclusion criteria for this study were vasopressor support and monitoring of serum triglycerides and creatinine. Her 72 patients, 61 male (84.7%) and 11 female (15.3%), met the study inclusion criteria. Of these, 3 men met his PRIS study definition and 1 died. The incidence of PRIS he had was 4.1% and the mortality rate was 33%. A positive linear correlation was observed between increased triglyceride levels and infusion time, but no correlation was observed between increased creatinine levels and infusion time. Elevated triglyceride levels may serve as a reliable biomarker for impending PRIS if confirmed in future investigations with larger sample sizes. Propofol is a popular sedative-hypnotic drug commonly used to induce general anesthesia and sedation in the intensive care unit (ICU). It is preferred over other available agents because of its rapid onset of action, rapid recovery from sedation, and low potential for nausea and vomiting. Propofol also offers several important physiological benefits that favor its use in the ICU, such as reduced cerebral metabolic demands, anticonvulsant properties, and neuroprotective effects. Despite these benefits, propofol rarely causes a fatal condition known as propofol infusion syndrome (PRIS). PRIS was first reported in children in his 1990s, and several adult cases were reported shortly thereafter. The term 'propofol-infusion syndrome' was coined by Bray in 1998 when he summarized 13 propofol-related childhood deaths. All these children presented with a similar spectrum of symptoms, including metabolic acidosis, serum hyperlipidemia, and refractory bradycardia that progressed to asystole. In 1996, Melinella was the first author to propose including propofol response in the differential diagnosis of metabolic acidosis that develops in adult patients during prolonged sedation with propofol. Then, in 1998, her first case of PRIS in an adult was reported. In this case, nearly all of her early manifestations of PRIS in pediatric patients have been reported, including hypoxia, metabolic acidosis, rhabdomyolysis, renal failure, and cardiac dysfunction. Despite over two decades of intensive research, the full pathophysiological mechanism responsible for PRIS has not been identified. A potential risk factor for PRIS was first identified in 1992 in his five case reports of relatively healthy children with acute epiglottitis or tracheobronchitis who died after sedation with propofol in the intensive care unit. . In these cases, pediatric patients treated long-term with high-dose propofol infusion developed refractory bradycardia that progressed to metabolic acidosis, serum lipidemia, and asystole. The aim of this retrospective descriptive study was to better define the incidence and demographics of his PRIS in a Level 1 trauma center, identify major risk factors for the development of this condition, and identify the relationship between elevated triglyceride levels and duration. It was to further establish the correlation.